A Phase I, Randomized, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of the Captisol Formulation of Vestipitant (GW597599) in Healthy Adult Subjects

Trial Profile

A Phase I, Randomized, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of the Captisol Formulation of Vestipitant (GW597599) in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Vestipitant (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
    • 12 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Sep 2011 Planned end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top